MedTrace Logo

Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.

NCT07748689 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2026-08-06

No results posted yet for this study

Summary

This study is testing whether a lower dose of belantamab mafodotin used together with pomalidomide and dexamethasone can provide similar effectiveness with fewer side effects compared with the standard dose in patients with relapsed or refractory multiple myeloma.

Participants will be randomly assigned to receive either a reduced dose or a standard dose of belantamab mafodotin in combination with pomalidomide and dexamethasone. The study will evaluate treatment response, side effects, and minimal residual disease (MRD), which is a measure of the number of myeloma cells that remain after treatment. The goal is to determine whether treatment can be optimized while maintaining disease control and reducing treatment-related toxicity.

Conditions

  • Relapsed / Refractory Multiple Myeloma

Interventions

DRUG

Belantamab Mafodotin

Belantamab mafodotin is administered intravenously in combination with pomalidomide and dexamethasone. The study evaluates a reduced-dose strategy versus a standard-dose strategy of belantamab mafodotin in patients with relapsed or refractory multiple myeloma.

DRUG

Pomalidomide

Pomalidomide is administered orally in combination with belantamab mafodotin and dexamethasone. Participants receive pomalidomide according to the protocol-defined treatment regimen

DRUG

Dexamethasone

Dexamethasone is administered orally in combination with belantamab mafodotin and pomalidomide. Participants receive dexamethasone according to the protocol-defined treatment regimen

Sponsors & Collaborators

  • Medical Research Agency, Poland

    collaborator OTHER_GOV

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Polish Myeloma Consortium

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2033-03-31
Completion
2033-03-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07748689 on ClinicalTrials.gov